Interim data analysis expected in Q1/Q2 1. B-OM
Post# of 72440
(Total Views: 218)
Posted On: 01/08/2017 7:15:08 PM
Interim data analysis expected in Q1/Q2
1. B-OM: The DSMB can stop the trial early if the result is excellent. The early start of B-UP indicates the early observation of patient case reports is positive.
2. P: IGA changes can be seen starting week 2 and clinical improvement can be seen starting week 4 in the 200 mg arm. PASI 75 is likely to be seen in the 300 mg or 400 mg arm within six weeks.
3. B-UP: Clinical meaningful improvement observed in cohort 1 (50 mg). Two patients achieved 100% reduction and two patients achieved 50% reduction. Cohort 2 will be 100 mg and cohort 3 will be 200 mg.
No wonder the same basher with different aliases start showing up to spread FUDs.
1. B-OM: The DSMB can stop the trial early if the result is excellent. The early start of B-UP indicates the early observation of patient case reports is positive.
2. P: IGA changes can be seen starting week 2 and clinical improvement can be seen starting week 4 in the 200 mg arm. PASI 75 is likely to be seen in the 300 mg or 400 mg arm within six weeks.
3. B-UP: Clinical meaningful improvement observed in cohort 1 (50 mg). Two patients achieved 100% reduction and two patients achieved 50% reduction. Cohort 2 will be 100 mg and cohort 3 will be 200 mg.
No wonder the same basher with different aliases start showing up to spread FUDs.
(3)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼